دراسة تربط أدوية GLP-1 بانخفاض خطر الإصابة بسرطان الثدي

6 يونيو، 2026

من إعداد الذكاء الاصطناعي

أظهرت دراسة رصدية موسعة أن احتمالات الإصابة بسرطان الثدي تنخفض بنحو 30 بالمئة لدى النساء اللواتي يتناولن أدوية GLP-1 مثل أوزمبيك (Ozempic) وويغوفي (Wegovy).

راجع الباحثون السجلات الصحية الإلكترونية لأكثر من 111,000 امرأة تتراوح أعمارهن بين 45 و80 عاماً، ممن لديهن مؤشر كتلة جسم يبلغ 25 أو أكثر، وخضعن لتصوير الثدي في مركز "بين ميديسن" (Penn Medicine) بين يناير 2022 ويونيو 2025. ووجدت الدراسة أن اللواتي وصف لهن أدوية GLP-1 كانت احتمالات إصابتهن بسرطان الثدي أقل بنسبة 35.1 بالمئة في المجموعة الكاملة، و30.5 بالمئة في تحليل مطابق. تم عرض النتائج في الاجتماع السنوي للجمعية الأمريكية لعلم الأورام السريري لعام 2026، ونُشرت في دورية "JCO Oncology Practice". وأشارت إليزابيث ماكدونالد، الأستاذة في كلية بيرلمان للطب بجامعة بنسلفانيا، إلى أن الدراسة رصدية ولا تثبت وجود علاقة سببية. وتخطط ماكدونالد وزملاؤها لإطلاق تجارب سريرية لاختبار ما إذا كانت أدوية GLP-1 يمكن أن تساعد في الوقاية من سرطان الثدي لدى النساء الأكثر عرضة للخطر. وتؤثر هذه الأدوية على المسارات المرتبطة بتطور السرطان، على الرغم من أن فقدان الوزن قد يساهم أيضاً في الفائدة الملحوظة.

Study finds people who use Ozempic-like drugs for weight loss face added stigma

5 مايو، 2026 من إعداد الذكاء الاصطناعي صورة مولدة بواسطة الذكاء الاصطناعي تم التحقق من الحقائق

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

High costs limit access to GLP-1 weight loss drugs

GLP-1 medications such as Ozempic, Wegovy and Zepbound deliver strong health value but create massive budget pressures for insurers. Researchers from the University of Mississippi highlight the gap between cost-effectiveness and affordability. Coverage remains restricted for many eligible patients.

Study links Ozempic to lower depression and anxiety risks

4 مايو، 2026 من إعداد الذكاء الاصطناعي

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

Health

Study links PAM gene variants to weaker blood-sugar response to GLP-1 drugs such as Ozempic

Health

Rutgers study finds GLP-1 drug use is tied to a weaker link between impulsivity and self-reported violence

Health

Updated POWER framework urges multidisciplinary obesity care beyond GLP-1 drugs

Study links GLP-1 drugs to modest hair loss risk

A new analysis of patient records shows that adults with type 2 diabetes who take GLP-1 receptor agonists face a higher rate of alopecia than those on other common diabetes medications.

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

8 مايو، 2026 من إعداد الذكاء الاصطناعي تم التحقق من الحقائق

A year-long observational study in Japan suggests that people with type 2 diabetes who tend to overeat in response to tempting food cues such as sight and smell may see greater weight loss—and possibly better blood-sugar improvement—after starting GLP-1 receptor agonists, while those with primarily emotional eating patterns show less consistent links to long-term outcomes.

Semaglutide linked to slower epigenetic aging signals in small HIV trials, researchers report

Semaglutide, the active ingredient in Ozempic and Wegovy, was associated with slower changes in DNA methylation–based “epigenetic clocks” in adults living with HIV in a post hoc analysis of a randomized, placebo-controlled trial. Scientists say larger studies are needed to determine whether these molecular signals translate into meaningful long-term health benefits.

Fibre boosting GLP-1 hormone approved for EU foods

1 يوليو، 2026 من إعداد الذكاء الاصطناعي

A modified fibre known as inulin-propionate ester has received safety approval from the European Food Safety Authority, paving the way for its addition to everyday products such as breads and cereals.

26 يوليو 2026 00:20

دراسة تربط أدوية GLP-1 بانخفاض خطر الإصابة بسرطان الثدي

مقالات ذات صلة

Study finds people who use Ozempic-like drugs for weight loss face added stigma

High costs limit access to GLP-1 weight loss drugs

Study links Ozempic to lower depression and anxiety risks

Study links PAM gene variants to weaker blood-sugar response to GLP-1 drugs such as Ozempic

Rutgers study finds GLP-1 drug use is tied to a weaker link between impulsivity and self-reported violence

Updated POWER framework urges multidisciplinary obesity care beyond GLP-1 drugs

Study links GLP-1 drugs to modest hair loss risk

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Semaglutide linked to slower epigenetic aging signals in small HIV trials, researchers report

Fibre boosting GLP-1 hormone approved for EU foods

Oral GLP-1 drugs reduce food reward signals in mice

Stanford scientists report appetite-suppressing peptide that reduced weight in mice and pigs

Claims-data study finds many people with type 2 diabetes restart GLP-1 drugs after stopping

Oral GLP-1 pill shows strong results in diabetes trial

Study: Physical activity fell after some patients with obesity started GLP-1 drugs

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

Study finds GLP-1 hormone at very low levels in arthritic joint fluid

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

Semaglutide shows strong weight loss results for adults over 65

Trojan horse obesity drug boosts weight loss in mice

يستخدم هذا الموقع ملفات تعريف الارتباط